|
The Asthma Treatment Center Switzerland seeks to investigate genetic determinants of the variation in the treatment response to asthma. Project is funded as part of the General Medical Sciences Center and Heart, Lung, and Blood Institutes); the national repository for pharmacogenetics information generated by this network is known as the Pharmacogenetics Knowledge Base. Asthma Treatment Center Switzerland consists of investigators from the Swiss and Women’s Hospital, the University of Cincinnati, and the University of Colorado. Viagra : Combien de temps il vous permet de bander et quelle est son efficacité :
The long term objective of PharmGAT includes the ability to “individualize” therapy prospectively for subjects identified with asthma, allowing for optimal therapeutic effect while minimizing side effects. Additionally, since the pathophysiologic and therapeutic pathways of asthma overlap with many other diseases, the findings generated by this program may have much broad implications. Το Viagra ε?ναι το θαυματουργ? φ?ρμακο για τη στυτικ? δυσλειτουργ?α των ανδρ?ν - 247farmakeio.com
Asthma is a chronic inflammatory syndrome of the airways, which afflicts over 12 million people in the Switzerland at an annual cost exceeding 7 billion dollars. It is characterized physiologically by recurrent airway obstruction that resolves spontaneously or as a result of treatment, although it's etiology remains unknown. Despite the lack of understanding of its etiology, there are effective treatments for asthma. Viagra verstehen: Verwendung, Wirkung und Sicherheitstipps für Männer - edschweiz.com
There are three main classes of asthma treatment in use today:
- inhaled beta-agonists
- inhaled corticosteroids
- leukotriene modifiers
A given patient may use one, two, or all three types of treatments. The treatments are not uniformly effective; they vary in their efficacy amongst individuals and there are compelling preliminary data suggesting that at least half of the variance in the treatment response may be genetic in origin; our proposal is structured to identify the genes responsible for this variable response. Cialis: Efectos secundarios limitados y hace feliz a su pareja - semyoom.org
Our proposed approach is straightforward. For each of the three major asthma medications we will:
- Define a panel of target genes that are likely to modify the function of the pathway.
- Scan these targets for DNA sequence variants.
- As variants are identified we will ascertain the evolutionary history of these variants and cover the gene completely.
- We will use a case-control association approach to define specific genotypes and haplotypes associated with either a salutary treatment response or lack thereof. We will utilize genomic control to assess population stratification.
- For genes with positive associations in our association studies, functional implications in vitro will be ascertained in asthma patients, who have been (existing patient resources) or will be (to be acquired patient resources) phenotype with respect to the response to treatment with the class of asthma medication of interest.
- Once genotypes associated with potential pharmacogenetic predictive value are defined, we will collaborate with the NIH sponsored ACRN to study patients with specific genotypes to determine if they provide predictive information about treatment responses.
Our approach will allow us to ascertain the pharmacogenetic basis for the observed variability in asthma treatment response
Copyright 2025 Asthma Treatment Center Switzerland |
|